# Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Source: https://onco.cc/trials/nct03260894/  
OnCo record `nct03260894` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pembrolizumab, Epacadostat, Sunitinib and Pazopanib in Renal cell carcinoma, run by Incyte Corporation, completed.

## Summary

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) is a phase 3 interventional study registered as NCT03260894 by Incyte Corporation, with 129 participants recorded, started 2017-12-07 and reaching its primary completion in 2018-08-22. Interventions recorded: Pembrolizumab, Epacadostat, Sunitinib, Pazopanib. Conditions recorded: Renal Cell Carcinoma (RCC).

Linked to the drug Epacadostat because the registry names it among its interventions and Renal cell carcinoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03260894
- Phase: 3
- Setting: A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)
- Sponsor: Incyte Corporation
- Enrolled: 129

## Sources

- ClinicalTrials.gov NCT03260894: https://clinicaltrials.gov/study/NCT03260894

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Epacadostat](https://onco.cc/drugs/epacadostat/), [Pazopanib](https://onco.cc/drugs/pazopanib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Sunitinib](https://onco.cc/drugs/sunitinib/)
- companies: [Incyte](https://onco.cc/companies/incyte/)

---
JSON: https://onco.cc/api/v1/entities/nct03260894.json